Search for a command to run...
<bold>Introduction:</bold> High frequency bronchoscopic microwave ablation (MWA) is a novel alternative to conventional lung cancer treatments. <bold>Aims:</bold> To investigate the feasibility of high frequency bronchoscopic MWA in patients with lung cancer. <bold>Methods:</bold> We report the interim results of a single arm prospective study enrolling subjects with confirmed malignant or highly suspicious pulmonary nodules ≤20mm, who are not surgical candidates. <bold>Results:</bold> 19 nodules were ablated in 19 subjects. Median age was 73 years. 68.4% were female. 58% of subjects had previous thoracic surgery, radiotherapy, or percutaneous ablation. 17 out of 19 high frequency MWA were delivered robotically. 58% of the nodules were solid; 42% were part-solid. Median baseline long axis nodule length was 9.9mm. Median distance was 15.1mm from pleura and 43.1mm from central zone. Median procedure time was 60 mins, with a median hospital stay length of 1 day. <table-wrap><object-id>erj;66/suppl_69/PA2928/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td><bold>Time post-ablation</bold></td><td> Day 1 (n=19) </td><td> Month 1 (n=16) </td><td> Month 3 (n=15) </td><td> Month 6 (n=12) </td><td> Month 12 (n=6) </td></tr><tr><td><bold>Median length of ablation zone</bold></td><td>27.1mm</td><td>21.6mm</td><td>17.1mm</td><td>16.2mm</td><td>14.5mm</td></tr></tbody></table></table-wrap> Median patient-reported outcomes are as follows (*p<0.05,**p<0.001 compared to baseline): <table-wrap><object-id>erj;66/suppl_69/PA2928/TB2</object-id><object-id>T2</object-id><object-id>TB2</object-id><table><colgroup><col></col><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td><bold>Time post-ablation</bold></td><td> Baseline (n=19) </td><td> Day 1 (n=19) </td><td> Month 1 (n=16) </td><td> Month 3 (n=15) </td></tr><tr><td><bold>EQ-5D Index (IQR)</bold></td><td>0.8 (0.2)</td><td>1.0 (0.2)**</td><td>0.8 (0.3)</td><td>0.8 (0.2)</td></tr><tr><td><bold>EQ-VAS Score (IQR)</bold></td><td>70 (25)</td><td>80 (20)*</td><td>80 (17.5)</td><td>80 (25)</td></tr><tr><td> <bold>Pain score</bold> <bold>(IQR)</bold> </td><td>0 (3.0)</td><td>0 (1.0)</td><td>0 (2.0)</td><td>0 (0)</td></tr></tbody></table></table-wrap> Disease progression occurred in 1 patient at 6 months, and 1 patient at 12 months. <bold>Conclusion:</bold> Interim data suggests high frequency bronchoscopic MWA may be a feasible alternative for treating patients with lung cancer who are not suitable for surgery, and is associated with low morbidity.